Heart failure & cardiomyopathiesCohort study
Clinical characteristics and outcomes of cardiomyopathies related to immune-mediated diseases
- Retrospective cohort study
- registry-based
- external validation cohort
Authors' conclusion
ID-CMP patients have a higher risk of MACE despite similar LVEF trajectories, as confirmed in a validation cohort.
Study context
- Population
- Patients with dilated cardiomyopathy, Maastricht Cardiomyopathy registryvalidation cohort 201 ID-CMP
- Participants
- 194 vs 678
- Exposure
- Immune-mediated dilated cardiomyopathy (DCM) vs non-immune DCM
- ID-CMPn = 194
- Non-immune DCMn = 678reference
- Outcome
- MACE:
- Cardiac mortality
- HF hospitalization
- Life-threatening arrhythmias
- Follow-up
- Median 5.2 (3.7-10.7) years
Main finding
MACE
Hazard ratio
1.68
CI 1.1–2.5
P = 0.012
ID-CMP vs Non-immune DCM
HR 1.68 (CI 1.1–2.5); P = 0.012
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (CI) | P value | |
|---|---|---|---|
| MACE, external validation cohort | 2.40 (1.6–3.5) | P < 0.001 | |
| Inflammation on EMB · worse clinical outcome | 2.0 (1.1–3.6) | P = 0.017 | |
| 0.20.5125Hazard ratio (log scale) |
Pathogenic DCM gene variants
P = ns
Left ventricular ejection fraction (LVEF) trajectories
- LVEF lower in ID-CMP during first year, converged thereafter
- P0-1year = .018; P>1year = ns
MACE by ID-CMP subtype
- Outcomes did not differ among ID-CMP subtypes
Original publication
Clinical characteristics and outcomes of cardiomyopathies related to immune-mediated diseases. Eur J Heart Fail. Published 2 February 2026. doi:10.1093/ejhf/xuaf030
Summarised from the published abstract; every number is checked against it